Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.
December 18, 2023
Share
Certain Restricted Stock Units of HilleVax, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. These Restricted Stock Units will be under lockup for 91 days starting from 19-SEP-2023 to 19-DEC-2023.
Details:
Directors, executive officers and one of significant stockholders (collectively, the lock-up parties) have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each lock-up party, with limited exceptions, for a period of 90 days after the date of this prospectus supplement (such period, the restricted period), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC and Leerink Partners LLC
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
HILLEVAX, INC. 
